Vericel Corporation Share Price & Technical Analysis
VCEL · $34.83 (+0.29%)
Healthcare / Biotechnology
$34.83
+0.29%
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the r…
Price chart
Seasonality
May has 3 positive and 1 negative years (last 5 years shown)
0% return in May, 5% avg return in past 3 year May month.
-1% return in 2026, 21% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -1% | -1% | -7% | 7% | 0% | – | – | – | – | – | – | – | -1% |
| 25 | 6% | -12% | -13% | -14% | 9% | 3% | -17% | 6% | -12% | 12% | 15% | -10% | -26% |
| 24 | 23% | 5% | 12% | -13% | 4% | -6% | 10% | 7% | -18% | 5% | 31% | -5% | 55% |
| 23 | 3% | 11% | -4% | 8% | 2% | 17% | -4% | -8% | 1% | 5% | 1% | 0% | 33% |
| 22 | -10% | 16% | -7% | -26% | -5% | -8% | 29% | -22% | -6% | 14% | -16% | 15% | -27% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Uptrend
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.68B
P/E ratio
76.33
52W high
$45.97
52W low
$28.95
Volume
1,09,520
Beta
1.16
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Vericel Corporation share price today?
- Vericel Corporation (VCEL) last traded around $34.83 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does VCEL have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for VCEL. Download the app for real-time alerts.
- How can I analyze Vericel Corporation stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.